Drug Therapy

David L. Longworth, MD
Chairman, Department of Infectious Diseases, Cleveland Clinic

Address: David L. Longworth, MD, Department of Infectious Diseases, S32, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

David L. Longworth, MD
Chairman, Department of Infectious Diseases, Cleveland Clinic

Address: David L. Longworth, MD, Department of Infectious Diseases, S32, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

David L. Longworth, MD
Chairman, Department of Infectious Diseases, Cleveland Clinic

Address: David L. Longworth, MD, Department of Infectious Diseases, S32, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Raed A. Dweik, MD
Staff Physician, Department of Pulmonary and Critical Care Medicine, Cleveland Clinic

Address: Raed A. Dweik, MD, Department of Pulmonary and Critical Care Medicine, A90,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland OH 44195; [email protected]

Dr. Dweik discusses therapies that are not yet labeled (FDA-approved) for the use under discussion or products that are still investigational.

Raed A. Dweik, MD
Staff Physician, Department of Pulmonary and Critical Care Medicine, Cleveland Clinic

Address: Raed A. Dweik, MD, Department of Pulmonary and Critical Care Medicine, A90,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland OH 44195; [email protected]

Dr. Dweik discusses therapies that are not yet labeled (FDA-approved) for the use under discussion or products that are still investigational.

Raed A. Dweik, MD
Staff Physician, Department of Pulmonary and Critical Care Medicine, Cleveland Clinic

Address: Raed A. Dweik, MD, Department of Pulmonary and Critical Care Medicine, A90,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland OH 44195; [email protected]

Dr. Dweik discusses therapies that are not yet labeled (FDA-approved) for the use under discussion or products that are still investigational.

M. Hilal Yamani, MD
Section of Heart Failure and Transplantation, Department of Cardiology, Cleveland Clinic

Address: M. Hilal Yamani, MD, Department of Cardiology, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

M. Hilal Yamani, MD
Section of Heart Failure and Transplantation, Department of Cardiology, Cleveland Clinic

Address: M. Hilal Yamani, MD, Department of Cardiology, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

M. Hilal Yamani, MD
Section of Heart Failure and Transplantation, Department of Cardiology, Cleveland Clinic

Address: M. Hilal Yamani, MD, Department of Cardiology, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Robert E. Hobbs, MD, FACC
Department of Cardiology, Section of Heart Failure and Cardiac Transplantation Medicine, Cleveland Clinic

Address: Robert F. Hobbs, MD, FACC, Department of Cardiology, Section of Heart Failure and Cardiac Transplantation Medicine, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Robert E. Hobbs, MD, FACC
Department of Cardiology, Section of Heart Failure and Cardiac Transplantation Medicine, Cleveland Clinic

Address: Robert F. Hobbs, MD, FACC, Department of Cardiology, Section of Heart Failure and Cardiac Transplantation Medicine, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Robert E. Hobbs, MD, FACC
Department of Cardiology, Section of Heart Failure and Cardiac Transplantation Medicine, Cleveland Clinic

Address: Robert F. Hobbs, MD, FACC, Department of Cardiology, Section of Heart Failure and Cardiac Transplantation Medicine, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Steven D. Mawhorter, MD
Department of Infectious Disease, Cleveland Clinic

Michael A. Lauer, MD
Department of Cardiology, Borgess Medical Center Research Institute, Kalamazoo, Michigan

Address: Steven D. Mawhorter, MD, Department of Infectious Disease, S32, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

This paper discusses treatment that is “off label,” ie, not FDA-approved.

Steven D. Mawhorter, MD
Department of Infectious Disease, Cleveland Clinic

Michael A. Lauer, MD
Department of Cardiology, Borgess Medical Center Research Institute, Kalamazoo, Michigan

Address: Steven D. Mawhorter, MD, Department of Infectious Disease, S32, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

This paper discusses treatment that is “off label,” ie, not FDA-approved.

Steven D. Mawhorter, MD
Department of Infectious Disease, Cleveland Clinic

Michael A. Lauer, MD
Department of Cardiology, Borgess Medical Center Research Institute, Kalamazoo, Michigan

Address: Steven D. Mawhorter, MD, Department of Infectious Disease, S32, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

This paper discusses treatment that is “off label,” ie, not FDA-approved.

Hani Jneid, MD
Department of Internal Medicine, Cleveland Clinic

Holly L. Thacker, MD, FACP
Head, Section of Women’s Health, Departments of General Internal Medicine and Obstetrics and Gynecology, Cleveland Clinic; Director of Women’s Health Track GIM Fellowship, Clinical Associate Professor of Medicine, Penn State University

Address: Holly L. Thacker, MD, FACP, Department of General Internal Medicine and Obstetrics and Gynecology, A91, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195;
[email protected]

This paper discusses treatment information that is “off-label,” ie, not approved by the Food and Drug Administration for the indication under discussion.

Hani Jneid, MD
Department of Internal Medicine, Cleveland Clinic

Holly L. Thacker, MD, FACP
Head, Section of Women’s Health, Departments of General Internal Medicine and Obstetrics and Gynecology, Cleveland Clinic; Director of Women’s Health Track GIM Fellowship, Clinical Associate Professor of Medicine, Penn State University

Address: Holly L. Thacker, MD, FACP, Department of General Internal Medicine and Obstetrics and Gynecology, A91, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195;
[email protected]

This paper discusses treatment information that is “off-label,” ie, not approved by the Food and Drug Administration for the indication under discussion.

Hani Jneid, MD
Department of Internal Medicine, Cleveland Clinic

Holly L. Thacker, MD, FACP
Head, Section of Women’s Health, Departments of General Internal Medicine and Obstetrics and Gynecology, Cleveland Clinic; Director of Women’s Health Track GIM Fellowship, Clinical Associate Professor of Medicine, Penn State University

Address: Holly L. Thacker, MD, FACP, Department of General Internal Medicine and Obstetrics and Gynecology, A91, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195;
[email protected]

This paper discusses treatment information that is “off-label,” ie, not approved by the Food and Drug Administration for the indication under discussion.

Brian F. Mandell, MD, PhD
Department of Rheumatic and Immunologic Diseases, Cleveland Clinic; Senior Associate Program Director, Internal Medicine Residency Program; Deputy Editor, Cleveland Clinic Journal of Medicine

Address: Brian F. Mandell, MD, PhD, Cleveland Clinic Journal of Medicine, NA32,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Dr. Mandell has indicated that he has received grant or research support from the Novartis, Smith-Kline, Centocor, Searle, and Merck corporations, and that this article discusses therapies that are not yet approved by the Food and Drug Administration for the use under discussion or that are still under investigation.

Brian F. Mandell, MD, PhD
Department of Rheumatic and Immunologic Diseases, Cleveland Clinic; Senior Associate Program Director, Internal Medicine Residency Program; Deputy Editor, Cleveland Clinic Journal of Medicine

Address: Brian F. Mandell, MD, PhD, Cleveland Clinic Journal of Medicine, NA32,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Dr. Mandell has indicated that he has received grant or research support from the Novartis, Smith-Kline, Centocor, Searle, and Merck corporations, and that this article discusses therapies that are not yet approved by the Food and Drug Administration for the use under discussion or that are still under investigation.

Brian F. Mandell, MD, PhD
Department of Rheumatic and Immunologic Diseases, Cleveland Clinic; Senior Associate Program Director, Internal Medicine Residency Program; Deputy Editor, Cleveland Clinic Journal of Medicine

Address: Brian F. Mandell, MD, PhD, Cleveland Clinic Journal of Medicine, NA32,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Dr. Mandell has indicated that he has received grant or research support from the Novartis, Smith-Kline, Centocor, Searle, and Merck corporations, and that this article discusses therapies that are not yet approved by the Food and Drug Administration for the use under discussion or that are still under investigation.